c-Met can be detected in about 70% of the different types of ovarian cancers such as low and high grade serous, endometrioid, clear cell and mucinous carcinomas, in about 30% of the tumors c-Met is expressed to a noticeably high degree [31–33]. This evidence concerns the gene MET and mucinous adenocarcinoma.